Methods and compositions for in vivo screening of therapeutics through spatial transcriptomics
Provided herein are compositions and methods of use thereof for screening a plurality of uniquely identifiable therapeutic moiety in vivo by identifying one or more reporters indicative of a cell state.
1. A method for identifying a candidate therapeutic moiety comprising:
(1) administering to an animal or an organoid a library of expression cassettes comprising:
(a) a plurality of nucleic acid sequences, each encoding a different therapeutic moiety operably linked to a therapeutic moiety barcode; and
(b) a plurality of nucleic acid sequences encoding one or more reporter constructs that alone or collectively are indicative of a cell state or a likelihood of a cell state of the cell;
(2) removing a tissue from said animal or organoid and placing a section of said tissue on a coated surface; wherein said surface coating comprises primers encoding a spatial barcode providing coordinates for each of various spots on said coated surface;
(3) detecting a change in a cell state or likelihood of a cell state of one or more cells of the animal or the organoid and coordinating the presence of said therapeutic moiety to a specific cell or location within said tissue section using said spatial barcode,
wherein detecting comprises performing spatial transcriptomic RNA sequencing of a population of cells to determine an amount of the candidate therapeutic moiety present in the population of cells, thereby identifying a candidate therapeutic moiety.
2. The method of claim 1 , wherein said tissue is permeabilized after being placed on a coating surface.
3. The method of claim 2 , wherein reverse transcription is performed on nucleic acid in said tissue in order to produce cDNA.
4. The method of claim 3 , wherein reverse transcription is performed on nucleic acid in said tissue in order to produce cDNA, RNA sequencing is performed on said cDNA, and wherein said RNA sequencing method comprises spatial transcriptomics.
5. The method of claim 4 , wherein a level of protein or oligonucleotide expression is measured in said tissue using immunohistochemistry or fluorescent in situ hybridization staining methods.
6. The method of claim 5 , wherein said staining method utilizes fluorescent probes selected from green fluorescent protein (GFP), red fluorescent protein (RFP), or the like.
7. The method of claim 6 , wherein said therapeutic moiety encodes for a secreted or cell-intrinsic signaling molecule involved in cell-cell signaling, or regulators thereof.
8. The method of claim 7 , wherein said coated surface is a glass slide.
9. The method of claim 1 , wherein the spatial barcodes in combination with the confirmed presence of a candidate therapeutic moiety allows mapping of the intervention's effect on all the cells contained within the specific spot, or adjacent spots, on the coated surface.
10. The method of claim 9 , wherein each expression cassette of the plurality of expression cassettes is packaged in a virus.
11. The method of claim 10 , wherein each expression cassette of the plurality of expression cassettes is packaged in an adeno-associated virus (AAV), adenovirus, or lentivirus.
12. The method of claim 11 , wherein the change in the cell state or a likelihood of the cell state correlates to a therapeutic effect resulting from the candidate therapeutic moiety.
13. The method of claim 12 , wherein the likelihood of the cell state correlates with a level of protein or oligonucleotide expression in the cell.
14. The method of claim 13 , wherein the therapeutic moiety encodes for a secreted factor.
15. The method of claim 14 , wherein the likelihood of the cell state is indicative to the cell receiving the candidate therapeutic moiety.
16. The method of claim 14 , wherein the likelihood of the cell state is indicative of a neighboring cell receiving a candidate therapeutic moiety.
17. The method of claim 16 , wherein the likelihood of the cell state is indicative of a cell receiving a secreted factor from a neighboring cell receiving a candidate therapeutic moiety.
18. A method for identifying a candidate therapeutic moiety comprising:
(1) administering to an animal or an organoid a library of expression cassettes that include:
(a) a plurality of nucleic acid sequences, each encoding a different therapeutic moiety operably linked to a therapeutic moiety barcode; and
(b) a plurality of nucleic acid sequences encoding one or more reporter constructs that alone or collectively are indicative of a cell state or a likelihood of a cell state of the cell;
(2) removing a tissue from said animal or organoid and placing a two-dimensional section of said tissue on a coated surface; wherein the coating comprises primers encoding a spatial barcode providing coordinates for each of various spots on said coated surface;
(3) identifying the location of therapeutic moieties through combined detection of therapeutic moiety barcodes and special barcodes;
(4) detecting a change in a cell state or likelihood of a cell state of one or more cells of the animal or the organoid using one or more selected from the group consisting of reporter constructs, histology, and transcriptomic analysis; and
(5) performing a weighted probability analysis to predict the likelihood of a cell state based on the cell's proximity to one or more therapeutic moieties in the tissue, thereby identifying a candidate therapeutic moiety,
wherein detecting comprises performing spatial transcriptomic RNA sequencing of a population of cells to determine an amount of the candidate therapeutic moiety present in the population of cells, thereby identifying a candidate therapeutic moiety.